Share on StockTwits

Equities researchers at Cowen and Company increased their price objective on shares of Amicus Therapeutics (NASDAQ:FOLD) to $14.00 in a research report issued on Wednesday. Cowen and Company’s target price indicates a potential upside of 206.35% from the company’s current price.

FOLD has been the subject of a number of other recent research reports. Analysts at Janney Montgomery Scott upgraded shares of Amicus Therapeutics from a “neutral” rating to a “buy” rating in a research note on Tuesday, July 1st. They now have a $5.00 price target on the stock, up previously from $2.50. Separately, analysts at Leerink Swann upgraded shares of Amicus Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, July 1st. They now have a $6.00 price target on the stock, up previously from $2.50. Finally, analysts at JPMorgan Chase & Co. upgraded shares of Amicus Therapeutics from a “neutral” rating to an “overweight” rating in a research note on Monday, June 30th.

Shares of Amicus Therapeutics (NASDAQ:FOLD) traded up 15.75% during mid-day trading on Wednesday, hitting $5.29. 13,265,476 shares of the company’s stock traded hands. Amicus Therapeutics has a 52 week low of $1.77 and a 52 week high of $4.74. The stock has a 50-day moving average of $4.1 and a 200-day moving average of $2.81. The company’s market cap is $416.3 million. Amicus Therapeutics also was the recipient of some unusual options trading activity on Tuesday. Investors acquired 5,148 put options on the company. This is an increase of 533% compared to the typical daily volume of 813 put options.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.31) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.23) by $0.08. Analysts expect that Amicus Therapeutics will post $-0.94 EPS for the current fiscal year.

Amicus Therapeutics, Inc (NASDAQ:FOLD) is a United States-based biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule drugs known as pharmacological chaperones for treating a range of diseases, including lysosomal storage diseases and diseases of neurodegeneration.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.